Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Public ClinicalTrials.gov record NCT00390806. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.
Study identification
- NCT ID
- NCT00390806
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 472 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2006 (Type not available)
- Primary completion
- Jul 2012 (Actual)
- Completion
- Sep 2013 (Actual)
- Last update posted
- Jan 20, 2014
2006 – 2013
United States locations
- U.S. sites
- 46
- U.S. states
- 24
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294 | — |
| GSK Investigational Site | Glendale | Arizona | 85304 | — |
| GSK Investigational Site | Hot Springs | Arkansas | 71913 | — |
| GSK Investigational Site | Anaheim | California | 92801 | — |
| GSK Investigational Site | Duarte | California | 91010-3000 | — |
| GSK Investigational Site | Pleasant Hill | California | 94523 | — |
| GSK Investigational Site | Aurora | Colorado | 80012 | — |
| GSK Investigational Site | Lakeland | Florida | 33805 | — |
| GSK Investigational Site | Tampa | Florida | 33606 | — |
| GSK Investigational Site | Tampa | Florida | 33612 | — |
| GSK Investigational Site | Chicago | Illinois | 60612 | — |
| GSK Investigational Site | Elk Grove Village | Illinois | 60007 | — |
| GSK Investigational Site | Galesburg | Illinois | 61401 | — |
| GSK Investigational Site | Park Ridge | Illinois | 60068 | — |
| GSK Investigational Site | Rockford | Illinois | 61108 | — |
| GSK Investigational Site | Skokie | Illinois | 60077 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46227 | — |
| GSK Investigational Site | Westwood | Kansas | 66205 | — |
| GSK Investigational Site | Paducah | Kentucky | 42003 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55455 | — |
| GSK Investigational Site | Jackson | Mississippi | 39216 | — |
| GSK Investigational Site | Columbia | Missouri | 65201 | — |
| GSK Investigational Site | Kansas City | Missouri | 64154 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68510 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89106 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89135 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87109 | — |
| GSK Investigational Site | Albany | New York | 12206 | — |
| GSK Investigational Site | Buffalo | New York | 14215-1199 | — |
| GSK Investigational Site | Buffalo | New York | 14215 | — |
| GSK Investigational Site | The Bronx | New York | 10467 | — |
| GSK Investigational Site | Columbus | Ohio | 43235 | — |
| GSK Investigational Site | Eugene | Oregon | 97401-8122 | — |
| GSK Investigational Site | Charleston | South Carolina | 29403 | — |
| GSK Investigational Site | Bedford | Texas | 76022 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78412 | — |
| GSK Investigational Site | Dallas | Texas | 75320-2510 | — |
| GSK Investigational Site | Duncanville | Texas | 75137 | — |
| GSK Investigational Site | Fort Worth | Texas | 76104 | — |
| GSK Investigational Site | Lubbock | Texas | 79415 | — |
| GSK Investigational Site | Sherman | Texas | 75090 | — |
| GSK Investigational Site | Sugarland | Texas | 77479 | — |
| GSK Investigational Site | Everett | Washington | 98201 | — |
| GSK Investigational Site | Vancouver | Washington | 98684 | — |
| GSK Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00390806, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2014 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00390806 live on ClinicalTrials.gov.